Growth Hormone Results Timeline: What Studies Measured, and When

What a "results timeline" means in the growth hormone literature

Growth hormone (GH) is one of the few peptide hormones with a large body of randomized, regulator-grade human trial data. That data, however, was not collected as a week-by-week diary of how participants felt. It was collected on a fixed measurement calendar: investigators chose a primary endpoint, chose the timepoint at which it would be assessed, and reported what the measurement showed at that point. Understanding the GH literature as a timeline therefore means understanding when trials looked, not when any individual might expect something to happen.

Across pediatric GH deficiency trials, one timepoint dominates: 12 months. The phase 3 study of weekly somatrogon versus daily somatropin in children with growth hormone deficiency used annual height velocity after 12 months of treatment as its efficacy comparison and reported that the weekly formulation met its non-inferiority objective against daily dosing (PMID 35405011). Adult trials used shorter windows and entirely different outcomes. Neither timeline transfers to the other population, and neither describes what a non-trial user would experience.

The measurement calendar used in pediatric trials

Children with GH deficiency are the most-studied population, and the trials are unusually consistent in structure: 12-month randomized main phases, growth measured by stadiometry at scheduled visits, and safety plus laboratory markers collected alongside.

Weeks 0 to 12: the part trials rarely reported separately

The first three months are the least-documented segment of the GH timeline in published reports, because almost no pivotal trial used an early timepoint as its primary endpoint. Growth in children is measured in centimetres per year, and short intervals produce measurement noise large enough to swamp the signal — which is why the phase 3 somapacitan trial in children anchored its efficacy comparison at 52 weeks rather than at an interim visit (PMID 36062966). What trials did collect early were laboratory and safety data. The systematic review and meta-analysis comparing long-acting growth hormone replacement with daily growth hormone in children with GH deficiency pooled efficacy, safety, quality-of-life and adherence outcomes across trials, with IGF-1 based monitoring reported alongside growth measures (PMID 37236413). IGF-1 is a pharmacodynamic marker — it indicates that the drug is engaging its axis, not that a clinical outcome has occurred.

Months 6 to 12: the primary endpoint window

This is where the pediatric evidence actually lives. The heiGHt trial randomized treatment-naïve children with growth hormone deficiency to weekly lonapegsomatropin or daily somatropin and assessed annualized height velocity across the 52-week trial period (PMID 34272849). REAL4 ran the same structural design for once-weekly somapacitan against daily growth hormone, with height velocity at week 52 as the efficacy anchor and tolerability reported over the same period (PMID 36062966). The somatrogon phase 3 study reported its 12-month annual height velocity comparison against daily somatropin in the same framework (PMID 35405011).

The practical reading: in the disease state where GH has the strongest randomized evidence, researchers designed the studies on the assumption that one year is the shortest interval in which the main outcome can be credibly measured. Trials of non-GH growth-promoting agents used comparable logic — a phase 2 trial of oral meclizine in children with achondroplasia was designed around growth-promotion endpoints rather than short-term symptom scales (PMID 41326861).

Adult trials used a different clock and different outcomes

Adult GH deficiency is not a growth problem, so the endpoints changed. The randomized phase 3 trial of once-weekly somapacitan in adults with GH deficiency used a 34-week randomized period and centred on truncal fat percentage as the body-composition outcome, with tolerability reported over the same period (PMID 32022863). That single design choice is instructive: when investigators wanted to detect a body-composition change in adults, the study ran for roughly eight months, not eight weeks.

Muscle and function outcomes in non-deficient or disease-specific adult populations are much thinner. A study of testosterone and recombinant human growth hormone in facioscapulohumeral muscular dystrophy examined anabolic outcomes in a rare neuromuscular disease and reported efficacy and safety findings in that specific population (PMID 40900971). One trial in one rare disease does not establish a general adult timeline, and the literature should not be read as if it does.

Multi-year timelines: when the endpoint is adult height

Some GH questions cannot be answered in a year at all. In idiopathic short stature, the outcome of interest is near-adult height, and the published analysis of efficacy, safety and outcomes of growth hormone treatment in children with idiopathic short stature addressed treatment sustained over years rather than a single-season response (PMID 40848513). Similarly, an analysis of outcomes in growth hormone-treated children with Noonan syndrome examined growth results in relation to PTPN11 mutation status, comparing genotype subgroups across treatment (PMID 35245205). That study is a useful reminder that the same treatment duration produced different measured outcomes in different genetic subgroups — timelines are population-dependent, not drug-dependent.

Where the human timeline data is thin — stated plainly

Several questions that get asked about growth hormone have no clean timeline answer in the verified literature:

• Healthy adults seeking body-composition or anti-aging outcomes. The Endocrine Society scientific statement on hormones and aging reviewed age-related changes across endocrine axes, including the GH/IGF-1 axis, and discussed the evidence and risks surrounding hormone interventions in older adults (PMID 37326526). That statement is a review of evidence quality, not a schedule of expected outcomes.
• Growth hormone secretagogues. A review of the safety and efficacy of growth hormone secretagogues summarized what was known about this class, including the gap between measurable hormonal effects and demonstrated clinical benefit (PMID 28400207). Secretagogues act on the ghrelin/GHS receptor system, and drug development in that system has extended well beyond growth: a randomized, double-blind, placebo-controlled study tested a GHSR blocker in people with alcohol use disorder, with endpoints unrelated to growth or body composition (PMID 39704175).
• Week-by-week subjective effects. No trial in this citation set was designed to report how participants felt at week 2, week 4 or week 6. Quality-of-life outcomes appeared in pooled form in the long-acting versus daily GH meta-analysis rather than as a weekly trajectory (PMID 37236413).

Adverse Events Across the Timeline: What Studies Report

Safety data in these trials were collected continuously and reported over the full study period, not at a single timepoint. The phase 3 somatrogon study reported safety alongside its 12-month efficacy comparison against daily somatropin in children with GH deficiency (PMID 35405011), and REAL4 described once-weekly somapacitan as well tolerated in children with GH deficiency over its randomized period (PMID 36062966). The heiGHt trial likewise reported safety findings for weekly lonapegsomatropin against daily somatropin in treatment-naïve children (PMID 34272849), and the adult phase 3 trial reported once-weekly somapacitan as well tolerated in adults with GH deficiency (PMID 32022863).

Pooled safety comparisons matter more than any single trial: the systematic review and meta-analysis of long-acting versus daily growth hormone in children with GH deficiency assessed safety together with efficacy, quality of life, adherence and cost-effectiveness (PMID 37236413). For non-prescribed or off-label use in older adults, the Endocrine Society scientific statement on hormones and aging addressed the risk side of hormone interventions in ageing populations (PMID 37326526), and the secretagogue review examined safety questions specific to that drug class (PMID 28400207).

How to read any growth hormone timeline claim

1. Ask which population. A 12-month height-velocity result in children with diagnosed GH deficiency (PMID 34272849) says nothing about an adult without deficiency.
2. Ask what was measured. Truncal fat percentage at week 34 in adults with GH deficiency (PMID 32022863) is a body-composition metric, not a subjective outcome.
3. Ask whether the timepoint was pre-specified. Pivotal pediatric trials pre-specified 12 months (PMID 35405011); claims about weeks 2 to 8 generally come from outside these trial reports.
4. Ask whether outcomes differ by subgroup. Genotype-stratified outcomes in Noonan syndrome showed that subgroup matters (PMID 35245205).
5. Ask about duration of follow-up. Near-adult-height questions in idiopathic short stature required years of observation (PMID 40848513).

Recombinant growth hormone products are prescription medicines approved for defined indications; growth hormone secretagogues sit in a different regulatory position, and the review of that class discussed the evidence base supporting their use (PMID 28400207).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any hormone, medication or health decision. Background on the hormone itself is covered in the growth hormone learn page.

References

• Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study (The Journal of Clinical Endocrinology and Metabolism, 2022)
• Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial (The Journal of Clinical Endocrinology and Metabolism, 2022)
• Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial (The Journal of Clinical Endocrinology and Metabolism, 2021)
• Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial (The Journal of Clinical Endocrinology and Metabolism, 2020)
• Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: A systematic review and meta-analysis (Pharmacological Research, 2023)
• Efficacy, safety, and outcomes of growth hormone treatment in children with idiopathic short stature (Growth Hormone & IGF Research, 2025)
• Outcomes in growth hormone-treated Noonan syndrome children: impact of PTPN11 mutation status (Endocrine Connections, 2022)
• Study of Testosterone and Recombinant Human Growth Hormone in Facioscapulohumeral Muscular Dystrophy (Neurology: Genetics, 2025)
• Hormones and Aging: An Endocrine Society Scientific Statement (The Journal of Clinical Endocrinology and Metabolism, 2023)
• The Safety and Efficacy of Growth Hormone Secretagogues (Sexual Medicine Reviews, 2018)
• A randomized, double-blind, placebo-controlled study of a GHSR blocker in people with alcohol use disorder (JCI Insight, 2024)
• Efficacy and Safety of Oral Meclizine for Growth Promotion in Children with Achondroplasia: A Phase 2 Clinical Trial (Calcified Tissue International, 2025)